# A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer

> **NCT05769725** · PHASE2 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 70 (estimated)

## Conditions studied

- Serplulimab,Gastric Cancer, Adjuvant Therapy

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** Docetaxel
- **DRUG:** S1

## Key facts

- **NCT ID:** NCT05769725
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2025-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769725, "A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05769725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*